Drug intelligence / Profile preview

SPARC1203

Development stage: Phase 2
Lead developer: SPARC
Modality: Small Molecules
Administration: Intranasal (nasal Spray)[1]

Overview

SPARC1203 is a small molecule drug developed by Sun Pharma Advanced Research Company Limited (SPARC) for the treatment of allergic rhinitis. It has been evaluated in a phase 2 clinical trial as a nasal spray for patients with seasonal allergic rhinitis, where its safety and efficacy were assessed. The precise mechanism of action remains undisclosed or unknown in public sources, and it does not appear to represent a novel mechanism of action compared to existing therapies. There are no approved indications or known adverse events reported publicly for this compound[1][2][3][7].

Beyond the preview

Go deeper on SPARC1203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPARC1203.

Explore the full profile